Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...

Patients with psoriasis aged 65 years and older achieve long-term responses to interleukin (IL)-17 and IL-23 inhibitors that are comparable with younger patients, despite experiencing slower early ...

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

IL-17抑制剂为合并多发性硬化症（MS）的皮肤病/风湿病患者提供了新的治疗选择。 通过系统分析42例患者数据（平均年龄45岁，58%为女性），发现主要适应症为轴型脊柱关节炎（axSpA，31%）、银屑病（PsO，26%）和银屑病关节炎（PsA，24%）。

(MENAFN- GlobeNewsWire - Nasdaq) Burlingame, CA, June 17, 2025 (GLOBE NEWSWIRE) -- The global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is expected to ...

A total of 2331 patients initiated treatment with tumor necrosis factor a (TNFa) inhibitors, which was the most frequently used medication. Methotrexate (n=1474), IL-17 inhibitors (n=1119), IL-23 ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The current study comprehensively included three types of biologics for the first time, i.e., TNF-α inhibitors, IL-17 inhibitors, and JAK inhibitors, involving 9 drugs (adalimumab, etanercept, ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.